India's Shilpa Medicare gains on launch of new version of cancer drug
03/04/2025 09:45
** Shares of Shilpa Medicare SHME.NS rise 4.7% to 678.5 rupees
** Co's partner, Amneal Pharma, launched IV administered-version of its cancer drug Boruzu
** Trading volume of ~500,000 shares is 1.4x its 30-day avg
** Stock has shed 20% so far this year
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026